<DOC>
	<DOCNO>NCT01115556</DOCNO>
	<brief_summary>This single-masked study compare intravitreally administer 0.5 mg ranibizumab 2.0 mg ranibizumab subject manifest persistent recurrent macular fluid le 30 day follow treatment intravitreal anti-VEGF therapy . Patients mask treatment assignment . The study duration anticipate 12 month enroll 30 subject . Patients randomize 2:1 either 2.0 mg ranibizumab 0.5mg ranibizumab .</brief_summary>
	<brief_title>A Pilot Study evaLuate Role High-dose rAnbizumab ( 2.0mg ) Management AMD Patients With perSistent/recurrenT Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy ( LAST Study )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Subfoveal neovascularization secondary AMD Best correct visual acuity study eye 20/30 20/400 use ETDRS chart Documentation presence subretinal fluid and/or cystoid macular edema SDOCT le 30 day follow least six month antiVEGF therapy Presence fibrosis , hemorrhage , hypofluorescent lesion obscure great 50 % CNV lesion Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Participation another simultaneous medical investigation trial Prior treatment antiVEGF therapy study eye within 30 day BSL Prior treatment triamcinolone study eye within 6 month BSL . Prior treatment dexamethasone study eye within 30 day prior BSL Past treatment PDT thermal laser study eye Intraocular surgery ( include cataract surgery ) study eye within 2 month precede BSL History vitrectomy surgery , submacular surgery , surgical intervention AMD study eye Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Uncontrolled glaucoma study eye ( defined IOP â‰¥ 30 mmHg despite treatment antiglaucoma medication ) History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . History allergy fluorescein , amenable treatment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>